Kalbe Genexine Biologics is a clinical-stage biotechnology company focused on licensing biologics and biosimilars in oncology and specialty areas, while also providing cGMP contract manufacturing services. The company addresses high unmet medical needs by improving patient outcomes and quality of life through its targeted therapeutic products.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
There is a need for more accessible and affordable biologics and biosimilars, particularly in oncology and other specialty areas, to improve patient outcomes and quality of life. Many patients lack access to advanced therapies due to high costs and limited availability in certain regions.
Solution
Kalbe Genexine Biologics (KGbio) focuses on licensing and commercializing biologics and biosimilars to address unmet medical needs in oncology and high-specialty therapeutic areas. KGbio aims to improve patient access to advanced therapies by bringing innovative biologics medical innovation to the international market. In addition to licensing activities, KGbio provides cGMP contract development and manufacturing services for biopharmaceuticals.
Target Audience
KGbio's primary customers include patients in need of advanced therapies for oncology and other specialty areas, as well as pharmaceutical companies seeking cGMP contract manufacturing services.
Features
- Licensing of novel biologics and biosimilars in oncology and high-specialty areas.
- cGMP contract development and manufacturing services for biopharmaceuticals.
- Focus on therapeutic areas including oncology.
- Products designed to improve patient outcomes and quality of life.